cpi-1205
Generic: Lirametostat·Code: CPI-1205
cpi-1205: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CONSTELLATION PHARMACEUTICALS INC (CNST) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Frequently asked questions
Who is developing cpi-1205?
cpi-1205 is being developed by CONSTELLATION PHARMACEUTICALS INC.
How many clinical trials involve cpi-1205?
BioSniper tracks 1 clinical trial involving cpi-1205.
Get deeper analysis on cpi-1205
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis